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Dipeptidyl peptidase 4 (DPP4) is expressed in various tissues, including the skin,
and DPP4 inhibitors, that are currently used for the treatment of diabetes, may be
effective also for complications of diabetes that affect the skin. To assess the role
of DPP4 in keratinocytes, after creating a scratch wound in a monolayer of NTCC
2544 cells, we evaluated DPP4 expression and monitored wound repair over time,
after treatment with the DPP4 inhibitor 1(((1-(hydroxymethyl)cyclopentyl)amino)acetyl)2,5-
cis-pyrrolidinedicarbonitrile (DPP4-In). Expression of DPP4 increased early and was
maintained up to 48 h following the scratch as shown by western blot and
immunostaining. Treatment with 10 mM DPP4-In reduced DPP4 expression and
significantly accelerated wound repair. This effect did not involve enhanced cell
proliferation as shown by MTT proliferation assay, the lack of changes of cell cycle profiles
and the slight inhibition of ERK phosphorylation. Enhancement of wound repair by DPP4
inhibition was prevented by the non-specific MMPs inhibitor GM6100 (5 mM). Treatment
with DPP4-In increased the expression of high mobility group box 1 (HMGB1), a substrate
of this enzyme, and exposure of NCTC 2544 cells to DPP4-In and exogenous HMGB1
(10 nM) produced a non-additive effect. Finally the healing promoting effect of DPP4-In
was prevented by pretreatment with a neutralizing anti-HMGB1 antibody. The present
results suggest that DPP4 inhibition contributes to enhanced wound healing by inducing
keratinocytes to migrate into a scratched area. This effect seems to be independent of
cell proliferation and involves enhanced production of HMGB1.
Keywords: skin, diabetes, keratinocytes, HMGB1
Introduction
CD26, a 110 kDa cell surface glycoprotein, is expressed in several cell types and is endowed with
dipeptidyl peptidase 4 (DPP4) activity in its extracellular domain (Ulmer et al., 1990; Ohnuma et al.,
2008). It acts as a serine peptidase that cleaves N-terminal dipeptides when proline, hydroxyproline
and alanine are present at the penultimate position (De Meester et al., 1992). In various cell types
CD26/DPP4 exerts different properties and, among others, it is involved in cell proliferation, signal
transduction, cytokine production and T cell activation (Hegen et al., 1997; Reinhold et al., 1998).
In the last several years the interest toward DPP4 enzymatic activity has greatly increased due to
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the ability of DPP4 to cleave the incretin hormone, glucagon-
like peptide-1 (GLP-1), an insulin secretagogue (Deacon et al.,
1995; Pauly et al., 1996). Inhibitors of DPP4 have been then
developed and are widely used as effective agents for the treatment
of type 2 diabetes mellitus (DMT2; Pratley and Salsali, 2007).
Interestingly, the effects of GLP-1 and GLP-1 analogs, as well as of
DPP4 inhibitors, that act by inhibiting the cleavage of endogenous
GLP-1, are not limited to the control of hyperglycemia, but
involve several other tissues and functions (Sortino et al., 2013;
Gallwitz, 2014). Particularly relevant appears the role of DPP4
in the skin (Fuchs et al., 2009). Interest in this regard has been
raised due to the frequently observed cutaneous complications
occurring during diabetes (Quondamatteo, 2014) and the ensuing
potential of DPP4 inhibitors to control them. Among cutaneous
complications, one of the most common, i.e., the reduced healing
capacity of diabetic skin (Falanga, 2005), seems to directly involve
DPP4. The kinetics of DPP4 expression after wound differs in
fact in control and ob/ob diabetic mice, and the reappearance
of DPP4, after an initial reduction of its expression, coincides
with a resolved wound condition in healthy animals, but with the
persistence of an inflammatory status, that impairs wound repair,
in diabetic mice (Schurmann et al., 2012). More importantly,
inhibition of the enzymatic activity results in enhanced re-
epithelialization in impaired wound healing in diabetic animals
(Schurmann et al., 2012). Improvement of wound repair by the
DPP4 inhibitor linagliptin has been related to increased levels of
GLP-1 in the wound area that would reduce the inflammatory
reaction impairing the re-epithelialization process. However,
factors that contribute to the reparative process in the skin are
complex and different cell types are involved. Very little data
exist regarding the role of DPP4 specifically in keratinocytes
although this cell type represents one of the major sources of
the enzyme in the skin and plays a crucial role in the reparative
process. In the present study attention has then been focused
specifically on keratinocytes in order to analyze the function of
DPP4 and the effect of its inhibition in an in vitromodel of wound
repair.
Materials and Methods
Drugs and Reagents
The DPP4 IV inhibitor III, 1(((1-(hydroxymethyl)cyclope-
ntyl)amino)acetyl)2,5-cis-pyrrolidinedicarbonitrile (DPP4-In)
(Merck Millipore, Darmstadt, Germany) was dissolved in
100% ethanol at an initial concentration of 100 mM and all
subsequent dilutions were made in water. Chemotaxis-HMGB1,
LPS-free (HMGBiotech, Milan, Italy) was dissolved in water
and recombinant human SDF-1a (Peprotech, Rocky Hill, USA)
was prepared in a 0.1% BSA solution. In-solution GM6001,
was from Calbiochem® (Merck KGaA, Darmstadt, Germany).
Mouse monoclonal anti-HMGB1 was from HMGBiotech and
anti-SDF1a and anti-CD26 were provided by Santa Cruz
Biotechnology (Santa Cruz, USA). Anti-ERK and –pERK
antibodies were from Cell Signaling (Milan, Italy). Secondary
antibodies IR680 and IR800 were provided by MMedical (Milan,
Italy). All cell culture plastics were from BD Falcon (Milan,
Italy) and common cell culture reagents including media, media
supplements, serum, trypsin, buffers and antibiotics were from
Invitrogen Srl (Milan, Italy). Mouse anti-a-tubulin and all other
reagents, unless otherwise specified were from Sigma Aldrich (St
Louis, USA).
Cell Cultures
NCTC 2544 human keratinocyte cells (Interlab Cell Line
Collection, Genoa, Italy) were grown at 37°C in an atmosphere
of 5% CO2 in DMEM supplemented with 10% FCS and
penicillin/streptomycin. Adult Normal Human Epidermal
Keratinocytes (N-HEK) and Human Adult Epidermal
Keratinocytes-Diabetic Type II (D-HEK) were maintained
at 37°C in an atmosphere of 5% CO2 in KGM-Gold Keratinocyte
Growth Medium supplemented with KGM-Gold BulletKit
(hydrocortisone 0.1%, transferrin 0.1%, epinephrine 0.05%,
gentamicin sulfate/amphotericin-B, 0.1%, bovine pituitary
extract, 0.4%, epidermal growth factor human recombinant,
0.1% and insulin 0.1%). Cells, media and supplements were
all from Lonza (Basel, Switzerland). The primary culture of
skin fibroblasts was obtained from the outgrowth of a skin
punch and grown in DMEM supplemented with 10% FCS and
penicillin/streptomycin.
Scratch Wound Assay
NCTC 2544 cells were deprived of serum and scratched with
a sterile P200 pipette tip according to a paradigm previously
described (Merlo et al., 2009). Serum deprivation was considered
necessary to reduce or abolish proliferation that could confound
evaluation of the cell migratory process. After removal of the
resulting debris by repeated washes, cells were subjected to
treatment and scratch wound closure was monitored by phase
microscopy capturing images of the same field with a 10X
objective at different times, as specified. The cell free area was
determined with the aid of the image processing software “Image
J” developed by NIH and in public domain.
Western Blot Analysis
NCTC 2544 cells, maintained in serum-deprived DMEM were
subjected to mechanical damage by multiple scratches using a
sterile P200 pipette tip. At different times after the induction of
the damage (24–96 h), cells were collected and lysed with RIPA
buffer, containing a protease and phosphatase inhibitor cocktail
mix (Sigma). Full lysis was obtained by sonication. The samples
were then centrifuged for 5 min at 4000 rpm to remove insoluble
material. Fifty-five to 65 mg of protein extract were separated by
SDS-PAGE and transferred to nitrocellulosemembranes (Hybond
ECL, Amersham Biosciences Europe GmbH) using a transblot
semidry transfer cell for 60 min at 0.8 mA/cm2. Membranes were
then blocked for 30 min in Odyssey Blocking Buffer diluted 1:1
with PBS-Tween20 0.1%, and processed for immunodetection
with the following antibodies: rabbit anti-CD26 (1:500), mouse
anti-HMGB (1:750), goat anti-SDF-1a (1:200), rabbit anti-ERK
and anti-phospho-ERK (1:500), mouse anti-a tubulin (1:6000;
Sigma-Aldrich) and IR680 and IR800 secondary antibodies
(1:10000). Detection of specific bands was carried out using LI-
COR Odyssey scanner.
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FIGURE 1 | Increase of DPP4 expression in NCTC 2544 keratinocytes
subjected to scratch wound. DPP4 expression is analyzed under basal
conditions (A) and following scratch wound (B,C). Expression of the enzyme
appears upregulated already 8 h after scratch (B) as shown by immunostaining
and its overexpression is maintained up to 48 h (C). In (A) immunostaining for
DPP4 (upper panel) and a bright field image (lower panel) of a NCTC2544
monolayer (10x magnification). In (B,C) bright field and immunofluorescence
images of the scratched area captured with a 10x (upper panels) and a 40x
(lower panels) magnification. Western blot analysis confirms the overexpression
at 24 and 48 h (D). Bars show densitometry vs a-tubulin and are
mean +=  SE of at least three independent determinations. *p < 0.05 vs
control as by one way ANOVA and Newman-Keuls test for significance.
Immunocytochemistry
NCTC 2544 cells were fixed in 4% paraformaldehyde,
permeabilized with 0.1% Triton X-100 and saturated with
3% BSA. Cells were then incubated with anti-CD26/DPP4 (1:
100) o/n followed by incubation with Alexa 488-conjugated
anti-rabbit antibody (1:300) for 60 min at room temperature.
Cell Cycle Analysis
NCTC 2544 cells were collected with gentle trypsinization, fixed
in ice-cold 70% ethanol, treated for 1 h at 37°C with 100 mg/ml
ribonuclease to remove RNA. Cells were then incubated with
50 mg/ml propidium iodide just prior to analysis of DNA content
and ploidy carried out by a Beckton Dickinson FC500 flow
cytometer. Data were processed with the ModFit software for cell
cycle analysis.
Statistics
Data shown are expressed as mean +=  SEM of independent
experiments each run in quadruplicates. All data were analyzed
by one-way and two-way ANOVA followed by Newman Keuls or
Bonferroni post hoc test for significance, as indicated. The level of
significance was set at p< 0.05.
Results
Human keratinocytes, NCTC 2544 cells, express DPP4 under
basal conditions, as detected by immunocytochemistry
(Figures 1A–C) and western blot (Figure 1D). When NCTC
2544 cells are subjected to injury by scratching the monolayer
to create a wound, the expression of DPP4 increases, especially
at the rim of the wound. Immunostaining shows that increased
expression is already present at 8 h (Figure 1B) and is maintained
48 h after scratch (Figure 1C). This increase is confirmed by
western blot analysis of proteins obtained from a monolayer
of NCTC 2544 cells exposed to multiple scratches. Enhanced
DPP4 is measurable at 24 h (the earliest time point analyzed) and
disappears at 72 h (Figure 1D). NCTC 2544 cells were subjected
to a scratch wound migration assay, in which the ability of cells to
migrate and cover the empty space is monitored. Untreated cells
tend to close the wound by about 60%within 48 h (Figures 2A,B).
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FIGURE 2 | Inhibition of DPP4 increases wound closure in a monolayer of
NTCC 2544 keratinocytes. Treatment with DPP4-In (10 mM) increases the
ability of keratinocytes to migrate into the empty area and to repair the wound at
all time points examined (A,B). Representative images of the wound repair over
time are reported in (A). This effect is accompanied by reduction of the expression
of DPP4 induced by scratch wound (scr), as by western blot analysis (C). Data
are mean +=  SE of 3–5 independent experiments each run in quadruplicates.
In (B), *p < 0.05 vs control by two-way ANOVA and Bonferroni post hoc test for
significance; *p < 0.05 vs unscratched and **p < 0.05 vs untreated scratch
(C) by one-way ANOVA and Newman-Keuls test for significance.
Treatment with a DPP4 inhibitor (DPP4-In), at the concentration
of 10mM, accelerates wound closure with an effect that appears to
be significantly different from control at all time points analyzed
(Figure 2B). NCTC 2544 cells exposed to 10mMDPP4-In for 24 h
also show a reduction of DPP4 overexpression induced by scratch
injury (Figure 2C). The effect of DPP4-In is exclusively due to
stimulation of migration and an effect on cell growth is excluded.
Treatmentwith increasing concentrations of the drug (from0.1 up
to 50mM) does not affect in fact cell proliferation, as measured by
the MTT proliferation assay (Figure 3A), and in parallel does not
modify cell cycle profiles, as revealed by flow cytometric analysis
of cell cycle (Figure 3B and table). In addition, inhibition of DPP4
decreases (at 15 min), or slightly but not significantly reduces
(at 3 h), the enhanced ERK phosphorylation induced by scratch
(Figure 3C). Increased migration of keratinocytes induced by
DPP4 inhibition seems to involve matrix metalloprotease (MMP)
activation. The effect of DPP4-In is in fact prevented when the
aspecific inhibitor of MMPs, GM6001, is used. Treatment of a
scratched NCTC 2544 culture with 5 mMGM6001, added 30 min
before DPP4-In, completely prevents the ability of the drug to
accelerate wound closure (Figure 4A). However, no significant
increase in the expression of MMP-2 and MMP-9 is detectable
following DPP4-In treatment, at least under the experimental
conditions that have been used (Figure 4B). The effect of DPP4
inhibition on scratch repair has been analyzed also in N-HEK as
well as in human adult epidermal keratinocytes obtained from
patients with type II diabetes (D-HEK). Basal expression of DPP4
does not differ between the two cell types, and scratch closure,
that proceeds very slowly in both cell types, is significantly
improved by chronic exposure to DDP4-In (10 mM) to a similar
extent in N-HEK (Figure 5A) and D-HEK (Figure 5B). Only a
slight shift to an earlier significant effect of DPP4 inhibition is
observed in D-HEK compared to N-HEK cells. In addition, the
favoring effect of wound repair is not restricted to keratinocytes,
as a better scratch repair is observed also following exposure of
human skin fibroblasts to 10 mMDPP4-In (Figure 5C).
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FIGURE 3 | The healing promoting effect of DPP4-In does not involve
increased cell proliferation. Treatment with increasing concentrations of
DPP4-In does not modify cell proliferation as from MTT assay (A). Cell cycle
analysis of NCTC 2544 cells treated with DPP4-In (10 mM) for 24 h does not
modify the distribution of cells in different phases of cell cycle, as by flow
cytometry after labeling of cells with propidium iodide. In (B), representative
profiles of control (left panel) and DPP4-In (right panel) treated cells. Data
summarized in the table are mean +=  SE of three independent experiments
each run in quadruplicates. In (C), the increased phosphorylation of ERK
induced by scratch wound is counteracted by DPP4-In (10 mM) treatment at
15 min and at 3 h. One representative plot is shown and expression of
a-tubulin is reported for loading control. Data were analyzed by one-way
ANOVA and Newman-Keuls test for significance. In (B), *p < 0.05 vs control
and **p < 0.05 vs scratch alone.
In search for possible mediators of the inhibition of DPP4 on
keratinocyte wound repair, HMGB1 and SDF1a were analyzed.
Both these agents are in fact reported to be substrates for DPP4
activity. Treatment of NCTC 2544 cells with 10 nM HMGB1
or 50 ng/ml SDF1a accelerates wound closure with an effect
already present at early time points (16 h) and persistent up to
48 h (Figure 6A). Co-treatment of NCTC 2544 cells with DPP4-
In (10 mM) and 10 nM HMGB1 produces an effect favoring
wound repair superimposable to that obtained with DPP4-In
alone (Figure 6B). In contrast, exposure of cells to DPP4-
In together with 50 ng/ml SDF1a causes an improved scratch
closure, significantly different from that induced by DPP4-In
alone (Figure 6B). Importantly, treatment withDPP4-In increases
the expression of HMGB1, as detected by western blot analysis
(Figure 6C), whereas expression of SDF-1a is not modified.
In addition, preincubation with a neutralizing anti-HMGB1
antibody (2.5 mg/ml) prevents the favoring effect of DPP4-In on
wound repair (Figure 6D). Conversely, treatment with an anti-
SDF1a antibody (5 mg/ml) fails to modify DPP4-In effect (not
shown).
Discussion
Linagliptin, a DPP4 inhibitor used in clinical practice for
the treatment of DMT2, has been reported to improve tissue
regeneration in diabetic mice (Schurmann et al., 2012). This
observation appears particularly relevant due to the impaired
wound healing that often occurs as a consequence of diabetes,
and the potential use of this class of drugs to control not only
hyperglycemia, but also diabetes complications that affect other
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B
A
FIGURE 4 | DPP4-In requires MMPs to promote wound repair. The cell
monolayer was scratched and pre-treated with the non-specific MMP inhibitor
GM6001 (5 mM) for 30 min prior to addition of DPP4-In (10 mM) (A). In (B)
representative blots of MMP2 and MMP9 24 h after scratch in the presence and
absence of DPP4-In are shown. Data reported are the % of scratch repair at
24 h and represent mean +=  SE of three independent experiments.
*p < 0.05 vs control and **p < 0.05 vs DPP4-In alone by one-way ANOVA and
Newman-Keuls test.
tissues. Attention then was driven to the expression of DPP4
in injured skin since data obtained in control and diabetic
mice reveal that high expression of the enzyme correlates with
persistence of an unresolved wound in diabetes (Schurmann
et al., 2012). Beside diabetes, the skin may represent a new target
organ for DPP4 inhibitors as the enzyme appears upregulated in
several skin pathological conditions (reviewed, in Thielitz et al.,
2008a).
Major sources of DPP4 in the skin are epidermal keratinocytes
and dermal fibroblasts. In the latter cell type, inhibition of
DPP4 has been related to reduction of cell proliferation and
counteraction of TGF-1-induced effects on collagen production,
matrix deposition and fibronectin expression (Thielitz et al.,
2008b). We here confirm that DPP4 is expressed also in
cultured keratinocytes (Reinhold et al., 1998; Vetter et al.,
2000) and report that in NCTC 2544 cells, a well characterized
human keratinocyte cell line, expression of DPP4 is increased
when a wound is mechanically produced in the monolayer.
Inhibition of the activity and expression of DPP4 results in
improved wound repair. This effect involves cell migration but
not keratinocyte proliferation, as from proliferation assay and
cell cycle analysis, and finds support in literature data, where
inhibition (Reinhold et al., 1998; Vetter et al., 2000) or no
effect (Schurmann et al., 2012) on keratinocyte proliferation by
DPP4 inhibition are reported. In addition, the increased ERK
phosphorylation induced by the scratch wound is inhibited by
treatment with DPP4-In, an effect already observed following
DPP4 inhibition in various cell types, including keratinocytes
(Thielitz et al., 2008b; Ta et al., 2010; Schurmann et al.,
2012).
Interestingly, increased keratinocyte migration and wound
closure induced by inhibition of DPP4 activity involves activation
of MMPs, as the pharmacological blockade of these enzymes
prevents enhanced wound repair. This indirect observation is
not supported by increased expression of the two MMPs mainly
involved with migration, i.e., MMP2 and MMP9. However,
this lack of effect is not completely unexpected as expression
of both enzymes is already high and the multiscratch model
adopted for quantitative analysis may limit detection of small
changes.
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FIGURE 5 | Inhibition of DPP4 increases scratch repair in different cell
types. Treatment with DPP4-In (10 mM) enhances wound repair in normal
human keratinocytes (N-HEK) (A), keratinocytes from diabetic patients
(D-HEK) (B) and fibroblasts from healthy human skin (C). In (A) and (B),
DPP4-In was added at time 0 and scratch repair was monitored for the
following 96 h. Data are mean +=  SE from three independent experiments
each run in quadruplicates. *p < 0.05 by Two-way ANOVA and Bonferroni
post hoc test for significance.
An accelerated wound healing by DPP4 inhibition is observed
also in primary cultures of keratinocytes from control and
diabetic patients. Both these cell cultures proceed very slowly
toward wound repair and only a slightly faster healing promoting
effect by DPP4-In is observed in cells from diabetic patients.
This difference cannot be ascribed to different levels of DPP4
in diabetic skin, according to the comparable expression of
DPP4 reported in control and ob/ob diabetic mice in intact skin
(Schurmann et al., 2012). However, it certainly deserves further
attention and other studies are needed to better characterize
DPP4 expression and its control in keratinocytes from
diabetic skin.
The increase of GLP-1 induced by DPP4 inhibition in the
wound area has been indicated as one of the mechanisms
involved in the facilitating effect of the healing process
(Schurmann et al., 2012). However, keratinocytes are only
target of GLP-1 and several other substrates of the enzyme
have been described (Mentlein, 1999). Of note, HMGB1 is
cleaved and inactivated by DPP4 (Marchetti et al., 2012), is
expressed in cultured fibroblasts and keratinocytes (Straino et al.,
2008) and DPP4 counteracts HMGB1-induced endothelial cell
migration and neovascularization (Marchetti et al., 2012). In
line with these observations, we now report that in cultured
keratinocytes inhibition of DPP4 causes increased cell migration,
very likely through enhanced HMGB1, as suggested by its
increased expression following DPP4 inhibition and prevention
of DPP4-In-healing promoting effect by treatment with a
neutralizing anti-HMGB1 antibody. Accordingly, HMGB1 exerts
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FIGURE 6 | HMGB1 is involved in the healing promoting effect of
DPP4-In. HMGB1 (10 nM) and SDF-1a (50 ng/ml) significantly increase wound
repair over time in scratched NCTC 2544 keratinocytes (A). Co-treatment with
DPP4-In (10 mM) and HMGB1 (10 nM) produces a non-additive effect (B),
whereas co-addition of DPP4-In and SDF-1a (50 ng/ml) potentiates repair
induced by DPP4-In alone (B). Western blot analysis shows that treatment with
DPP4-In (10 mM, 24 h) counteracts the reduction of HMGB1, but not that of
SDF-1a induced by scratch (C). In (D), treatment with a neutralizing
anti-HMGB1 antibody (2.5 mg/ml) prevents the increase of scratch repair
induced by treatment with DPP4-In (10 mM). Data are mean +=  SE of three to
four independent experiments. In (A) and (B), *p < 0.05 vs control; xp < 0.05
vs DPP-In alone. In (C), *p < 0.05 vs control and **p < 0.05 vs scratch alone;
in (D), *p < 0.05 vs control and **p < 0.05 vs DPP4-In alone. All data were
analyzed by one-way ANOVA and Newman-Keuls test for significance.
chemotactic effect on fibroblasts and keratinocytes in vitro
(Straino et al., 2008), accelerates wound closure in HaCAT
cultured keratinocytes (Ranzato et al., 2009) and 3T3 mouse
fibroblasts (Ranzato et al., 2010) and improves wound healing
in diabetic animals (Straino et al., 2008). Although HMGB1 has
been shown to be involved in migratory processes in different
cell types (Rauvala and Rouhiainen, 2010), it has been argued
that an increase of HMGB1 may be deleterious to cells due to
its proinflammatory properties (Schaper and Havekes, 2012).
However, we here suggest HMGB1 as a mediator of keratinocyte
migration induced by DPP4 inhibition, an effect that may be
distinct from its global action in the skin. Furthermore, an
increase of HMGB1 following treatment with DPP4 inhibitors
has been shown (Marchetti et al., 2012), but the use of this
class of antidiabetic drugs in clinical practice has never been
associated with appearance of inflammatory effects in various
tissues (Schaper and Havekes, 2012).
Finally, our results do not support the possibility that SDF1a,
another well described DPP4 substrate, mediates in keratinocytes
the improved wound healing induced by DPP4 inhibition.
However, despite the major role of SDF1a in wound repair,
including diabetic wound healing, these results could be at
least partially expected, considering that the major constitutive
sources of SDF1a in the skin are not keratinocytes, but
endothelial cells and fibroblasts (Avniel et al., 2006; Toksoy et al.,
2007).
In conclusion, our results show that inhibition of DPP4
increases the ability of keratinocytes to repair a scratch wound
in vitro. This effect involves HMGB1 but not SDF1a, two well
established substrates of DPP4 endowed with cell migration
enhancing properties. The data confirm that DPP4 inhibitors,
currently used in clinics for the treatment of DMT2, may
be effective also against skin complications that occur during
diabetes.
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